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Abstract
Background: Trypanosoma cruzi, causative agent of Chagas disease, displays high intraspecific genetic diversity: six
genetic lineages or discrete typing units (DTUs) are currently recognized, termed TcI through TcVI. Each DTU
presents a particular distribution pattern across the Americas, and is loosely associated with different transmission
cycles and hosts. Several DTUs are known to circulate in Central America. It has been previously suggested that TcI
infection is benign and does not lead to chronic chagasic cardiomyopathy (CCC).
Findings: In this study, we genotyped T. cruzi parasites circulating in the blood and from explanted cardiac tissue
of an El Salvadorian patient who developed reactivation Chagas disease while on immunosuppressive medications
after undergoing heart transplant in the U.S. as treatment for end-stage CCC. Parasite typing was performed
through molecular methods (restriction fragment length polymorphism of polymerase reaction chain amplified
products, microsatellite typing, maxicircle sequence typing and low-stringency single primer PCR, [LSSP-PCR]) as
well as lineage-specific serology. We show that the parasites infecting the patient belong to the TcI DTU exclusively.
Our data indicate that the parasites isolated from the patient belong to a genotype frequently associated with
human infection throughout the Americas (TcIDOM).
Conclusions: Our results constitute compelling evidence in support of TcI DTU’s ability to cause end-stage CCC
and help dispel any residual bias that infection with this lineage is benign, pointing to the need for increased
surveillance for dissemination of this genotype in endemic regions, the USA and globally.
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Findings
Chagas disease, caused by Trypanosoma cruzi, is the most
important parasitic disease in Latin America, [1] and
constitutes an emerging global public health problem, since
thousands of T. cruzi- infected Latin Americans migrated
during the last few decades and now live in North America,
Europe, Australia, Japan and other regions [2]. A spectrum
of clinical manifestations may result from human infection
with T. cruzi, ranging from a total absence of symptoms to
extremely debilitating and often deadly cardiac or digestive
syndromes [3], and T. cruzi’s genetic diversity is suspected
to influence the clinical outcome. Six major genetic lineages
or discrete typing units (DTUs) are currently recognized
(named TcI through TcVI), each displaying different
biological characteristics [4]. There are as yet no proven
associations between T. cruzi genetic lineages and the
clinical presentations of the disease; DTUs TcII, V and VI
are frequently reported to be present in the Southern Cone
of South America where serious chronic manifestations
include megaesophagus and megacolon, whereas TcI is
reported to predominate in endemic countries north of the
Amazon [4]. The pathogenicity of this lineage is evident
in acute cases, where patent clinical manifestations, in-
cluding death, have been reported in TcI oral outbreaks
[5]. However, in terms of chronic symptoms, TcI has
been suggested to be benign [6], with observed chronic
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chagasic cardiomyopathy (CCC) in TcI-infected patients
attributed to co-infection with other T. cruzi DTUs.
Despite being based on limited sampling, this view has
been reiterated in additional publications [7–9]. Further-
more, it has also been suggested that Chagas disease may
be less severe among patients in the Amazon basin, where
TcI infection is likely [10]. TcI exhibits high intra-lineage
diversity, with members of a widely dispersed subgroup
(termed TcIDOM) associated with many human infections
[11], although no direct link with clinical manifestations
has been established.
Here, we report a case of chronic chagasic cardiomy-
opathy and reactivation disease accompanied by
extensive molecular characterization of the T. cruzi
parasites involved. A 43 year old chagasic patient from
El Salvador was admitted to Massachusetts General
Hospital to undergo orthotropic heart transplantation.
Immunofluorescence assay to detect anti-T. cruzi IgG
previously performed at the Centers for Disease
Control & Prevention (CDC, Atlanta, USA) was posi-
tive at >1:256 (diagnostic threshold > 1:32). His cardiac
symptoms corresponded to New York Heart Association
class IV and he had a biventricular pacemaker/defibrillator
for complete heart block. Fifteen months previously, he
underwent mitral valve replacement, tricuspid valve re-
construction and partial left ventriculectomy, at which
time a left ventricle excision and atrial appendage biopsy
showed active and healed myocarditis, consistent with late
phase Chagas disease. He had no other known etiologies
for his heart failure. Orthotropic heart transplantation was
successful. Pathologic examination of the explanted heart
revealed findings consistent with end-stage CCC, includ-
ing dilatation with near complete atrophy of the left
ventricular wall, endocardial fibrosis, diffuse myocardial
Fig. 1 Molecular typing from clinical samples. DNA was extracted from blood samples and parafinized heart explants. Typing was performed using a
nested PCR-RFLP strategy for amplification of the 1f8 flagellar protein and digestion with Alw 21I (Van der Auwera, et al., unpublished data). H = DNA
extracted from parafinized heart explant tissue, B and B2 = blood samples taken 10 days apart during reactivation of disease, TcI-TcVI correspond to
DTU controls, NC lanes correspond to negative controls for the PCR and nested-PCR. Lanes corresponding to Alw 21I restriction digest products are
labeled with an asterisk (*). Only restriction products are shown for controls
Fig. 2 Molecular typing for cultured parasites and parasite clones. DNA was extracted from epimastigote hemocultures (HC) and five derived
clones (CL1-CL5). TcI-TcVI correspond to DTU controls, NC corresponds PCR negative control. Lanes containing restriction products are labeled
with an asterisk (*). Only restriction products are shown for controls. DNA was analyzed by the PCR-RFLP scheme proposed by Lewis, et al., 2009
[12]: as indicated by the brackets on the right side, fragments from the LSUrDNA, HSP60 and GPI genes were amplified by PCR. GPI and HSP60
products were digested with HhaI and EcoRV restriction enzimes, respectively
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fibrosis, and mononuclear infiltrates with some eosino-
phils and neutrophils. The infiltrate (lymphocytic myocar-
ditis) was composed of lymphocytes (many CD3 T cells,
more CD8 than CD4, few CD20 B cells) plus many CD68
macrophages. Amastigotes were not identified on multiple
sections examined; however, T. cruzi kinetoplast DNA was
detected by PCR in frozen tissue submitted to the Parasitic
Diseases and Diagnostics Branch of the CDC. Weekly
microscopic examination of his blood was performed after
transplant, screening for early detection of reactivation
disease; this was positive with rare trypomastigotes detected
at week six after transplant. He was given nifurtimox
8-10 mg/kg (as 120 mg four times a day) orally for 10 weeks,
and developed severe peripheral neuropathy with anorexia.
He was switched to benznidazole, 150 mg twice a day
for 30 days, which he tolerated well, and his peripheral
neuropathy and anorexia resolved. He was monitored
monthly for parasitemia for approximately one year
after the end of therapy, with no evidence of further
infection.
Genotyping directly from patient’s blood samples and
parafinized heart explants using a nested PCR-RFLP for the
Fig. 3 Neighbour joining dendrogram based on pairwise inverse allele sharing. Relationship between parasite clones isolated from the patient
and others from North, Central and South America are shown. Branch colours indicate strain origin and values at important nodes indicate
percentage of bootstrap support over 1000 trees. Further details of strains and analytical strategy can be found in [11]
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Fig. 4 Maxicircle sequence-based typing of strain isolated from patient. Maxicircle sequences for one biological clone were concatenated (accession #
KP136828) according to [14], aligned against 70 TcI strains encompassing TcI genetic diversity from across North, Central and South America [11] and used
to assemble a Maximum-Likelihood topology in PhyML. The best-fit model of nucleotide substitution was selected from 88 models and its significance
evaluated according to the Akaike Information Criterion (AIC) in jMODELTEST 1.0. The best fit model selected for this dataset was GTR +G. Bootstrap
support for clade topologies was estimated following the generation of 100 pseudo-replicate datasets
Fig. 5 LSSP-PCR. DNA from parafinized heart explants and blood samples was amplified using the S35/S36 primer pair. The 330 bp product was
gel-purified and analyzed by LSSP-PCR. Products were run in a 10 % polyacrilamide gel and silver-stained. H1 and H2 correspond to DNA extracted from
two different sections of parafinized heart explant tissue B and B2 correspond to blood samples taken 10 days apart, starting six weeks after transplant.
Cl3 corresponds to DNA from one of the clones derived from the original T. cruziisolate. Y indicates “Y strain” parasites (TcII DTU) used for comparison.
MWM=molecular weight markers
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1f8 flagellar protein and digestion with Alw21I restriction
enzyme (Van der Auwera, unpublished) assigned parasites
to DTU TcI (Fig. 1). Hemoculture six and eight weeks after
transplant yielded epimastigotes, which were cloned in solid
medium. Cultured parasites and clones were determined to
belong to DTU TcI by polymerase chain reaction and
restriction fragment length polymorphism (PCR-RFLP) as
in [12] (Fig. 2). Intra-TcI genotyping was performed with
nuclear microsatellites [13] and maxicircle gene fragments
[14]. Intriguingly, microsatellite data indicate a close re-
lationship with TcIDOM, a distinct genotype within DTU
TcI which is common among human cases in Latin
America (Fig. 3), while the maxicircle sequence analysis
indicates an origin among wild/non-human isolates for
North and Central America (Fig. 4). Additionally,
LSSP-PCR [15] showed matching patterns among DNA
extracted from patient blood samples, heart explants
and cultured parasite clones, indicating that they repre-
sent the same parasite population. Meanwhile, Y-strain,
from the TcII lineage, employed as a control, yielded a
completely different amplification pattern (Fig. 5).
Finally, although patient’s serum reacted against T. cruzi
antigen in three different commercial serological tests
(Chagatek-Biomerieux, Chagas III-Abbott BiosChile and
Chagatest Recombinante 3.0-Wiener Lab), it did not
recognize synthetic peptides derived from the TSSA anti-
gen specific for DTUs TcII, III, IV or V/VI described in
[16]. Therefore, we conclude that the observed CCC was
caused by TcI, unequivocally confirming that TcI is an
agent of life threatening heart disease.
TcI constitutes the most abundant and widespread T.
cruzi DTU [4] and is the predominant DTU in the Amazon
region and countries North of it [1]. For our patient, only
TcI DTU parasites were detectable in the clinical samples,
hemocultures, and biologically cloned parasites from hemo-
culture. Furthermore, antibodies against TcII, III, IV or V/
VI - specific peptide epitopes were not detectable in serum,
suggesting the absence of co-infection or previous infection
with those lineages; there is currently no adequately sensi-
tive equivalent TcI-specific serological assay [16].
TcI has considerable intra-DTU diversity [13]; specific
genotypes within TcI are associated with human infection
[11]. Based on nuclear microsatellite information, the
patient was infected by TcIDOM, a genotype associated
with many human infections in regions north of the Ama-
zon. TcIDOM has not previously been reported from car-
diac tissues in CCC cases, as it has been merely detected
in peripheral blood or hemoculture, where co-infection
with parasites from other genetic lineages causing CCC
cannot be ruled out. Remarkably, mitochondrial genotyp-
ing suggests a closer relationship with isolates from North
and Central America, consistent with local, possibly syl-
vatic, origin of the infecting strain. Given the proclivity for
mitochondrial introgression into TcIDOM [11, 14, 17, 18] we
suggest our observation represents yet another such hybrid
among many, in this case between TcIDOM and a local
strain, highlighting the need for control strategies aimed at
domiciliary and extrinsic parasite populations as sources of
human infection.
The case portrayed herein highlights many of the chal-
lenges that may arise when encountering a case of CCC
(end-stage heart failure, need for heart transplant, Chagas
disease reactivation under immune suppression, adverse
reaction to parasiticidal treatment) which were very compe-
tently handled by a capable medical team in a non-endemic
nation. Awareness of Chagas disease as an emerging global
problem is essential for successfully meeting such chal-
lenges, which are predicted to be faced with increased
frequency in non-endemic countries.
Furthermore, the results of our molecular characteriza-
tion constitute compelling evidence in support of the role
of TcI as causative agent of end-stage CCC and help dispel
any residual bias that infection with this lineage is benign.
Considering the broad distribution of TcI (the only T.
cruzi DTU ranging from the Southern United States to
Argentina and Chile) and the frequency with which TcI
strains are associated with human infection [4], there is
need for greater surveillance in TcI endemic regions like
Central America. Around 22 million people from Chagas
endemic countries live in the US, and most of these immi-
grants come from Mexico (74 %) and El Salvador (6.4 %)
[2], where TcI is known to predominate [4]. Thus, a signifi-
cant proportion of the estimated 300,000T. cruzi infections
among immigrants in the U.S.A. are predicted to involve
the DTU TcI, adding to the growing economic burden of
medical care and interventions associated with Chagas
disease in the U.S.A., including transplantation for end-
stage heart disease.
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